Friday, November 13, 2026
Wedbush starts Mentari Therapeutics coverage with Outperform rating and $33 price target
Wedbush began covering Mentari Therapeutics with an Outperform rating. The firm set a $33 price target on the shares.
Tuesday, November 10, 2026
Jefferies starts Mentari Therapeutics coverage with Buy rating and $30 price target
Jefferies began covering Mentari Therapeutics and gave the shares a Buy rating. The firm set a $30 price target on the stock.
Stifel starts Mentari Therapeutics coverage with Buy rating and $30 price target
Stifel began covering Mentari Therapeutics and rated the shares Buy. The firm set a $30 price target on the stock.
Frequently asked questions
What is the latest news on MTRI?
Nov 13, 2026: Wedbush starts Mentari Therapeutics coverage with Outperform rating and $33 price target (Benzinga) · Nov 10, 2026: Jefferies starts Mentari Therapeutics coverage with Buy rating and $30 price target (Benzinga) · Nov 10, 2026: Stifel starts Mentari Therapeutics coverage with Buy rating and $30 price target (Benzinga)
Get MTRI news as it happens
Every headline, SEC filing and analyst action for MTRI on your live chart, with important news marked and alerts when it matters.
Try SEPT Free